Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is ... NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 1.3698630137 | 1.46 | 1.68 | 1.38 | 24695 | 1.51051833 | CS |
| 4 | -0.3 | -16.8539325843 | 1.78 | 1.94 | 1.29 | 25284 | 1.5722228 | CS |
| 12 | -0.86 | -36.7521367521 | 2.34 | 2.75 | 1.29 | 139737 | 1.88561493 | CS |
| 26 | -1.01 | -40.562248996 | 2.49 | 2.75 | 1.29 | 120297 | 1.90250362 | CS |
| 52 | -1.01 | -40.562248996 | 2.49 | 2.75 | 1.29 | 120297 | 1.90250362 | CS |
| 156 | -1.01 | -40.562248996 | 2.49 | 2.75 | 1.29 | 120297 | 1.90250362 | CS |
| 260 | -1.01 | -40.562248996 | 2.49 | 2.75 | 1.29 | 120297 | 1.90250362 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
